Jan Trøst Jørgensen

11PUBLICATIONS
5CO-AUTHORS
Molecular targetsMedical biotechnology diagnostics (incl. biosensors)Gene and molecular therapyCancer diagnosisPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 04, 2026
FDA 2025 Cancer Drug Approvals: targeted therapy dominates.

|Nov 07, 2025
Companion diagnostics and HER2-targeted antibody-drug conjugates.

Jan Trøst Jørgensen, Kristian Egebjerg

|Aug 05, 2024
Human Epidermal Growth Factor Receptor 2 Pan Tumor Indication for Trastuzumab Deruxtecan.

Jan Trøst Jørgensen, Kristian Egebjerg, Anne-Vibeke Lænkholm

|Jun 24, 2024
Twenty-five years with HER2 targeted therapy.

Jan Trøst Jørgensen

|May 13, 2024
MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations.

Jan Trøst Jørgensen, Edyta M Urbanska, Jens Mollerup

|Feb 12, 2024
The impact of companion diagnostic testing on medical decision making and IVD regulations.

Jan Trøst Jørgensen

Pageof 2

Frequent Collaborators

3 joint publications

Jens Mollerup

1 joint publications

Edyta M Urbanska

1 joint publications

Kristian Egebjerg

1 joint publications

Anne-Vibeke Lænkholm